Skip to main content
Hauptrubriken
CME
Facharzt-Training
Webinare
Zeitschriften
Bücher
e.Medpedia
Podcast
Service
Jobbörse
Info & Hilfe
Fachgebiete
Anästhesiologie
Allgemeinmedizin
Arbeitsmedizin
Augenheilkunde
Chirurgie
Dermatologie
Gynäkologie und Geburtshilfe
HNO
Innere Medizin
Kardiologie
Neurologie
Onkologie und Hämatologie
Orthopädie und Unfallchirurgie
Pädiatrie
Pathologie
Psychiatrie
Radiologie
Rechtsmedizin
Urologie
Zahnmedizin
Themen
Klimawandel und Gesundheit
Neues aus dem Markt
COVID-19
Praxis und Beruf
Seltene Erkrankungen
GOÄ & EBM
Panorama
Sammlungen
Kasuistiken
Algorithmen & Infografiken
Blickdiagnosen
Videos
Kongressberichte
Medizin für Apothekerinnen und Apotheker
Für Ärztinnen und Ärzte in Weiterbildung
Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
coloproctology
Erschienen in: coloproctology 3/2021

14.06.2021 | Analkarzinom | Leitlinien

S3-Leitlinie Analkarzinom

Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen

verfasst von: Prof. Dr. med. Felix Aigner, MBA, PD Dr. med. Robert Siegel, Dr. med. Ricardo N. Werner, PD Dr. med. Stefan Esser, Prof. Dr. med. Mark Oette, PD Dr. med. Gerhard Weyandt, Prof. Dr. med. Volker Kahlke, Dr. med. Adal Saeed, Prof. Dr. med. Matthias Turina, Dr. med. Franz A. Mosthaf, Prof. Dr. med. Stefan Dresel, PD Dr. med. Steffen Simon, Prof. Dr. med. Gerald Niedobitek, Dr. med. Stephan Koswig, Prof. Dr. Volker Budach, Dr. med. Jan Schmielau, Prof. Dr. med. Hans-Rudolf Raab, Dipl. med. Gerhard Faber, Dr. rer. medic. Bianca Senf, Prof. Dr. med. Claus Rödel, Prof. Dr. med. E. Fokas, Dr. med. Rolf Mahlberg, Dr. med. Maria Steingräber, Prof. Dr. med. Johannes Weßling, Prof. Dr. med. Ulrike Wieland, Prof. Dr. med. Alois Fürst, Dr. med. Petra Lugger, Prof. Dr. med. Franz‑Josef Prott, Dr. med. Irmgard Kronberger, Dr. med. Stephan Baumeler, Dr. Christine Maurus, Erich Grohmann, Matthew Gaskins, MPH, Gabriela L. Avila Valle, M.Sc., Martin Dittmann, Deutsche Gesellschaft für Koloproktologie, Deutsche AIDS Gesellschaft, Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten, Deutsche Dermatologische Gesellschaft, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie – AG Coloproktologie, Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie – AG „Funktionalität in der kolorektalen Chirurgie“, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Deutsche Gesellschaft für Nuklearmedizin, Deutsche Gesellschaft für Palliativmedizin, Deutsche Gesellschaft für Pathologie, Deutsche Krebsgesellschaft – AG Onkologische Pathologie, Deutsche Gesellschaft für Radioonkologie, Deutsche Gesellschaft für Rehabilitationswissenschaften, Deutsche Krebsgesellschaft – Assoziation Chirurgische Onkologie, Deutsche Krebsgesellschaft – AG Onkologische Rehabilitation und Sozialmedizin, Deutsche Krebsgesellschaft – AG Psychoonkologie, Deutsche Krebsgesellschaft – AG Radiologische Onkologie, Deutsche Krebsgesellschaft – AG Supportive Maßnahmen in der Onkologie, Deutsche Röntgengesellschaft, Gesellschaft für Virologie, Paul-Ehrlich-Gesellschaft für Chemotherapie, Berufsverband der Coloproktologen Deutschlands, Berufsverband der Deutschen Strahlentherapeuten, Österreichische Arbeitsgemeinschaft für Coloproktologie, Schweizerische Arbeitsgemeinschaft für Koloproktologie, Deutsche ILCO

Erschienen in: coloproctology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Analkarzinom ist zwar ein relativ seltener Tumor, zeigt aber einen kontinuierlichen Anstieg der Neuerkrankungen mit einer Verdoppelung der Inzidenz in den letzten 20 Jahren. Fast alle Analkarzinome werden durch eine persistierende Infektion mit humanen Papillomviren (HPV) induziert. Im Leitlinienprogramm Onkologie wurde unter Federführung der Deutschen Gesellschaft für Koloproktologie e. V. erstmals eine deutschsprachige S3-Leitlinie zur Optimierung von Diagnostik, Therapie und Nachsorge dieser Erkrankung erstellt. Anhand der formulierten Schlüsselfragen wurden in den interdisziplinären Arbeitsgruppen Empfehlungsvorschläge erarbeitet, die im Rahmen von nominalen Konsensusverfahren modifiziert und graduiert wurden. Im Rahmen des GRADE-Verfahrens erfolgte nach Durchführung der systematischen Literaturrecherche die endpunktbezogene Bewertung und Klassifikation der Evidenz. Zu den Themen Prävention und Screening, Diagnostik und Staging, supportive Maßnahmen vor und während der zielgerichteten Tumortherapie, Therapie des Analkarzinoms im Stadium I–III, Responsebeurteilung nach primärer Radiochemotherapie, Nachsorge, Therapie des residualen oder rezidivierenden Analkarzinoms, Therapie des metastasierten Analkarzinoms (Stadium IV), Palliativversorgung und Rehabilitation wurden insgesamt 93 Empfehlungen und Statements formuliert. Die neue S3-Leitlinie bietet eine Grundlage für die Optimierung der interdisziplinären und sektorenübergreifenden Versorgung der Betroffenen. Anhand von Qualitätsindikatoren sollten zukünftige Versorgungsforschungskonzepte untersuchen, inwieweit die Leitlinienempfehlungen berücksichtigt werden und dies zu einer Verbesserung der Versorgung beiträgt.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Anmerkung: Die Dosierung von 10 mg/m2 alle 2 Wochen liegt weit über der in anderen Indikationen zugelassenen Dosierung von 2 mg/kg Körpergewicht oder 200 mg absolut jeweils alle 3 Wochen und kommt daher nicht mehr zur Anwendung.
 
2
Wenn im Folgenden von „Palliativversorgung“ gesprochen wird, sind immer beide Formen, d. h. die allgemeine und spezialisierte Palliativversorgung gemeint. Sollte nur eine der Formen gemeint sein, wird dies explizit benannt.
 
Literatur
1.
Amin MB et al (2017) AJCC cancer staging manual, 8. Aufl. Springer, Cham
2.
Balshem H et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406 PubMed
3.
Guyatt GH et al (2011) GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 64(4):407–415 PubMed
4.
Guyatt GH et al (2011) GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64(12):1283–1293 PubMed
5.
Guyatt GH et al (2011) GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 64(12):1294–1302 PubMed
6.
Guyatt GH et al (2011) GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol 64(12):1303–1310 PubMed
7.
Guyatt GH et al (2011) GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64(12):1277–1282 PubMed
8.
Meerpohl JJ et al (2012) GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect. Z Evid Fortbild Qual Gesundhwes 106(6):449–456 PubMed
9.
Andrews J et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66(7):719–725 PubMed
10.
Kaminski-Hartenthaler A et al (2014) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Z Evid Fortbild Qual Gesundhwes 108(7):413–420 PubMed
11.
12.
Andrews JC et al (2013) GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 66(7):726–735 PubMed
13.
Alonso-Coello P et al (2016) GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 353:i2089 PubMed
14.
15.
Benson AB 3rd et al (2012) Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10(4):449–454 PubMed
16.
Geh I et al (2017) Association of coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017)—anal cancer. Colorectal Dis 19(Suppl 1):82–97 PubMed
17.
Glynne-Jones R et al (2014) Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii10–iii20 PubMed
18.
Moureau-Zabotto L et al (2017) Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis 49(8):831–840 PubMed
19.
20.
Lin C, Franceschi S, Clifford GM (2018) Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis 18(2):198–206 PubMedPubMedCentral
21.
Rodel F et al (2015) Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer 136(2):278–288 PubMed
22.
McBride AA, Warburton A (2017) The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog 13(4):e1006211 PubMedPubMedCentral
23.
Bernardi MP et al (2015) Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncol 16(16):e611–e621 PubMed
24.
Berry JM et al (2014) Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer 134(5):1147–1155 PubMed
25.
Gosens KC, Richel O, Prins JM (2017) Human papillomavirus as a cause of anal cancer and the role of screening. Curr Opin Infect Dis 30(1):87–92 PubMed
26.
Machalek DA et al (2012) Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 13(5):487–500 PubMed
27.
Amirian ES et al (2013) Anal cancer incidence and survival: comparing the greater San-Francisco bay area to other SEER cancer registries. Plos One 8(3):e58919 PubMedPubMedCentral
28.
Arens Y et al (2019) Risk of invasive anal cancer in HIV-infected patients with high-grade anal dysplasia: a population-based cohort study. Dis Colon Rectum 62(8):934–940 PubMedPubMedCentral
29.
Mathews WC et al (2014) Natural history of anal dysplasia in an HIV-infected clinical care cohort: estimates using multi-state Markov modeling. Plos One 9(8):e104116 PubMedPubMedCentral
30.
Cachay E, Agmas W, Mathews C (2015) Five-year cumulative incidence of invasive anal cancer among HIV-infected patients according to baseline anal cytology results: an inception cohort analysis. HIV Med 16(3):191–195 PubMed
31.
Tong WW et al (2015) Human papillomavirus 16-specific T‑cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions. J Infect Dis 211(3):405–415 PubMed
32.
Jiang Y, Ajani JA (2012) Anal margin cancer: current situation and ongoing trials. Curr Opin Oncol 24(4):448–453 PubMed
33.
Valvo F et al (2019) Cancer of the anal region. Crit Rev Oncol Hematol 135:115–127 PubMed
34.
Gatta G et al (2017) Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncol 18(8):1022–1039 PubMed
35.
Van Dyne EA et al (2018) Trends in human Papillomavirus-associated cancers—United States, 1999–2015. Mmwr Morb Mortal Wkly Rep 67(33):918–924 PubMedPubMedCentral
36.
Nielsen A, Munk C, Kjaer SK (2012) Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978–2008. Int J Cancer 130(5):1168–1173 PubMed
37.
Wilkinson JR et al (2014) The rising incidence of anal cancer in England 1990–2010: a population-based study. Colorectal Dis 16(7):O234–O239 PubMed
38.
Daling JR et al (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101(2):270–280 PubMed
39.
Daling JR et al (1987) Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317(16):973–977 PubMed
40.
Holly EA et al (1989) Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 81(22):1726–1731 PubMed
41.
Silverberg MJ et al (2012) Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 54(7):1026–1034 PubMedPubMedCentral
42.
Chaturvedi AK et al (2007) Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 99(21):1634–1643 PubMed
43.
Hemminki K, Dong C, Vaittinen P (2000) Second primary cancer after in situ and invasive cervical cancer. Epidemiology 11(4):457–461 PubMed
44.
Lin C et al (2019) Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis 19(8):880–891 PubMedPubMedCentral
45.
Saleem AM et al (2011) Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol 117(3):643–649 PubMed
46.
Sunesen KG et al (2010) Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978–2005. Int J Cancer 127(3):675–684 PubMed
47.
Meeuwis KA et al (2012) Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation 93(9):914–922 PubMed
48.
Alloub MI et al (1989) Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 298(6667):153–156 PubMedPubMedCentral
49.
Grulich AE et al (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59–67 PubMed
50.
Ogunbiyi OA et al (1994) Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients. Br J Surg 81(3):365–367 PubMed
51.
Patel HS et al (2010) Human papillomavirus infection and anal dysplasia in renal transplant recipients. Br J Surg 97(11):1716–1721 PubMedPubMedCentral
52.
Madeleine MM et al (2013) HPV-related cancers after solid organ transplantation in the United States. Am J Transplant 13(12):3202–3209 PubMedPubMedCentral
53.
Aigner F et al (2007) Malignancies of the colorectum and anus in solid organ recipients. Transpl Int 20(6):497–504 PubMed
54.
Daling JR et al (1992) Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 135(2):180–189 PubMed
55.
Nordenvall C et al (2011) Smoking, snus use and risk of right-and left-sided colon, rectal and anal cancer: a 37-year follow-up study. Int J Cancer 128(1):157–165 PubMed
56.
Phillips DH et al (2004) Smoking-related DNA adducts in anal epithelium. Mutat Res 560(2):167–172 PubMed
57.
Beaugerie L et al (2018) High risk of anal and rectal cancer in patients with anal and/or Perianal Crohn’s disease. Clin Gastroenterol Hepatol 16(6):892–899e2 PubMed
58.
59.
Gross GE et al (2018) S2k-Leitlinie: HPV-assoziierte Lasionen der ausseren Genitalregion und des Anus – Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung). J Dtsch Dermatol Ges 16(2):242–256 PubMed
60.
61.
Esser S et al (2015) German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. J Dtsch Dermatol Ges 13(12):1302–1319 PubMed
62.
63.
Fenger C et al (2000) Tumours of the anal canal. In: Hamilton SR, Aaltonen LA (Hrsg) World health organization classification of tumours: pathology and genetics of tumours of the digestive system. IARC Press, Lyon
64.
Grabenbauer GG et al (2005) Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum 48(9):1742–1751 PubMed
65.
Gunderson LL et al (2013) Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98–11 phase 3 trial. Int J Radiat Oncol Biol Phys 87(4):638–645 PubMedPubMedCentral
66.
Goffredo P et al (2018) A national-level validation of the new American Joint Committee on cancer 8th edition subclassification of stage IIA and B anal squamous cell cancer. Ann Surg Oncol 25(6):1654–1660 PubMed
67.
Correa JH et al (2013) Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. J Surg Oncol 107(5):486–492 PubMed
68.
Faivre JC et al (2018) Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). Radiother Oncol 129(3):463–470 PubMed
69.
Kapacee ZA et al (2016) Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors. Colorectal Dis 18(11):1080–1086 PubMed
70.
Glynne-Jones R et al (2013) Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 119(4):748–755 PubMed
71.
Ajani JA et al (2010) Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 116(17):4007–4013 PubMed
72.
Bartelink H et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15(5):2040–2049 PubMed
73.
Crum-Cianflone NF et al (2010) Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 24(4):535–543 PubMed
74.
Pappou EP et al (2018) Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: does HAART influence outcomes? World J Surg 42(3):876–883 PubMedPubMedCentral
75.
Wieghard N et al (2016) HIV positivity and anal cancer outcomes: a single-center experience. Am J Surg 211(5):886–893 PubMed
76.
Marcus JL et al (2015) Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev 24(8):1167–1173 PubMedPubMedCentral
77.
Coghill AE et al (2015) Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33(21):2376–2383 PubMedPubMedCentral
78.
Palefsky JM et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365(17):1576–1585 PubMed
79.
80.
81.
82.
Silverberg MJ et al (2015) Cumulative incidence of cancer among persons with HIV in north America: a cohort study. Ann Intern Med 163(7):507–518 PubMedPubMedCentral
83.
Richel O et al (2015) Brief report: anal cancer in the HIV-positive population: slowly declining incidence after a decade of cART. J Acquir Immune Defic Syndr 69(5):602–605 PubMed
84.
85.
Revollo B et al (2020) Routine screening of anal cytology in persons with human Immunodeficiency virus and the impact on invasive anal cancer: a prospective cohort study. Clin Infect Dis 71(2):390–399 PubMed
86.
87.
Ontario Medical Advisory Secretariat (2007) Anal dysplasia screening: evidence-based analysis. Ont Health Technol Assess Ser 7:45
88.
Giani I et al (2013) The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery. Tech Coloproctol 17(2):171–179 PubMed
89.
Wells JS et al (2014) An integrative review of guidelines for anal cancer screening in HIV-infected persons. AIDS Patient Care STDS 28(7):350–357 PubMed
90.
Leeds IL, Fang SH (2016) Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg 8(1):41–51 PubMedPubMedCentral
91.
Stewart DB et al (2018) The American Society of Colon and rectal surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018). Dis Colon Rectum 61(7):755–774 PubMed
92.
Moscicki AB et al (2015) Screening for Anal Cancer in Women. J Low Genit Tract Dis 19(3 Suppl 1):S27–S42 PubMed
93.
Brickman C, Palefsky JM (2015) Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr Hiv/aids Rep 12(1):6–15 PubMed
94.
Morton M, Melnitchouk N, Bleday R (2018) Squamous cell carcinoma of the anal canal. Curr Probl Cancer 42(5):486–492 PubMed
95.
Roberts JR, Siekas LL, Kaz AM (2017) Anal intraepithelial neoplasia: a review of diagnosis and management. World J Gastrointest Oncol 9(2):50–61 PubMedPubMedCentral
96.
Oette M et al (2017) Anal chromoendoscopy using gastroenterological video-endoscopes: a new method to perform high resolution anoscopy for diagnosing intraepithelial neoplasia and anal carcinoma in HIV-infected patients. Z Gastroenterol 55(1):23–31 PubMed
97.
Goldie SJ et al (1999) The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 281(19):1822–1829 PubMed
98.
Silling S et al (2012) Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men. J Clin Virol 53(4):325–331 PubMed
99.
Hillman RJ et al (2019) International anal neoplasia society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis 23(2):138–146 PubMed
100.
Ong JJ et al (2014) Regional and national guideline recommendations for digital ano-rectal examination as a means for anal cancer screening in HIV positive men who have sex with men: a systematic review. Bmc Cancer 14(25081485):557 PubMedPubMedCentral
101.
Kreuter A et al (2016) High-grade Dysplasia in Anogenital warts of HIV-positive men. JAMA Dermatol 152(11):1225–1230 PubMed
102.
Schlecht HP et al (2010) Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis 51(1):107–110 PubMed
103.
Glynne-Jones R et al (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 18(3):347–356 PubMedPubMedCentral
104.
105.
Scholefield JH, Harris D, Radcliffe A (2011) Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis 13(Suppl 1):3–10 PubMed
106.
Chai CY et al (2018) Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg 153(3):209–215 PubMed
107.
Deshmukh AA et al (2018) Clinical and economic evaluation of treatment strategies for T1N0 anal canal cancer. Am J Clin Oncol 41(7):626–631 PubMedPubMedCentral
108.
Kynaston JWF et al (2018) Management of early anal squamous cell cancer: observational cohort study. Colorectal Dis 20(Supplement 4):105
109.
Hocquelet A et al (2018) Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy. Eur Radiol 28(7):2801–2811 PubMed
110.
Otto SD et al (2009) Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg 13(7):1292–1298 PubMed
111.
Reginelli A et al (2017) Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer. Oncotarget 8(14):22980–22990 PubMedPubMedCentral
112.
Mahmud A, Poon R, Jonker D (2017) PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol 90(1080):20170370–28972796 PubMedPubMedCentral
113.
Sekhar H et al (2017) Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. Lancet Oncol 18(10):1348–1359 PubMed
114.
Wade DS et al (1989) Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surg Gynecol Obstet 169(3):238–242 PubMed
115.
Bhuva N, Harrison M (2011) To pet or not to pet? That is the question. Staging in anal cancer. Ann Oncol 22:v126–v127
116.
117.
Cotter SE et al (2006) FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 65(3):720–725 PubMed
118.
Mistrangelo M et al (2012) Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 84(1):66–72 PubMed
119.
Pepek JM, Willett CG, Czito BG (2010) Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw 8(1):123–129 PubMed
120.
Trautmann TG, Zuger JH (2005) Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 7(4):309–313 PubMed
121.
Jones M et al (2015) The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol 22(11):3574–3581 PubMed
122.
Sabbagh A et al (2019) Is there a role for an 18F-fluorodeoxyglucose-derived biological boost in squamous cell anal cancer? Clin Oncol R Coll Radiol 31(2):72–80 PubMed
123.
Rusten E et al (2017) Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography. Radiat Oncol 12(1):147–28874205 PubMedPubMedCentral
124.
Noorani A et al (2013) Systematic review of sentinel lymph node biopsy in anal squamous cell carcinoma (Provisional abstract). Int J Surg 11:762–766 PubMed
125.
Tehranian S et al (2013) Sentinel node mapping in anal canal cancer: systematic review and meta-analysis (Provisional abstract). J Gastrointest Liver Dis 22:321–328
126.
Hagemans JAW et al (2018) Salvage abdominoperineal resection for squamous cell anal cancer: a 30-year single-institution experience. Ann Surg Oncol 25(7):1970–1979 PubMedPubMedCentral
127.
Tanum G et al (1991) Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 67(10):2462–2466 PubMed
128.
Arnott SJ et al (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5‑fluorouracil, and mitomycin. Lancet 348(9034):1049–1054
129.
Pawlik TM et al (2007) Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol 14(10):2807–2816 PubMed
130.
Abdel-Nabi H et al (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206(3):755–760 PubMed
131.
Llamas-Elvira JM et al (2007) Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 34(6):859–867 PubMed
132.
Akiyoshi T et al (2009) Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis 11(5):464–469 PubMed
133.
Furukawa H et al (2006) Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 55(7):1007–1011 PubMedPubMedCentral
134.
Kam MH et al (2010) Comparison of magnetic resonance imaging-fluorodeoxy-glucose positron emission tomography fusion with pathological staging in rectal cancer. Br J Surg 97(2):266–268 PubMed
135.
136.
137.
Mai SK et al (2007) The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. Radiat Oncol 2:30 PubMedPubMedCentral
138.
Chin-Hong PV, Reid GE, AST Infectious Diseases Community of Practice (2019) Human papillomavirus infection in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice</i>. Clin Transplant 33(31077438):e13590–9 PubMed
139.
Seo Y et al (2009) Outcomes of chemoradiotherapy with 5‑Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 75(1):143–149 PubMed
140.
141.
Giuliano AR et al (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364(5):401–411 PubMedPubMedCentral
142.
Harder T et al (2018) Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med 16(1):110 PubMedPubMedCentral
143.
Coskuner ER et al (2014) Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study. J Sex Med 11(11):2785–2791 PubMed
144.
Hildesheim A et al (2016) Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 215(2):212e1–212e15
145.
Wilkin TJ et al (2018) A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: aIDS clinical trials group protocol A5298. Clin Infect Dis 67(9):1339–1346 PubMedPubMedCentral
146.
Schiller J, Lowy D (2018) Explanations for the high potency of HPV prophylactic vaccines. Vaccine 36(32 Pt A):4768–4773 PubMedPubMedCentral
147.
GlaxoSmithKline (2019) Fachinformation Cervarix
148.
MSD Sharp & Dohme (2019) Fachinformation GARDASIL(R) 9
149.
Cooper R et al (2012) Defunctioning stomas prior to chemoradiation for anal cancer are usually permanent. Colorectal Dis 14(1):87–91 PubMed
150.
Glynne-Jones R et al (2014) Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Ann Oncol 25(8):1616–1622 PubMed
151.
Sunesen KG et al (2011) Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin Oncol 29(26):3535–3540 PubMed
152.
Poynter L et al (2015) P‑134 The prevalence and fate of the defunctioning stoma in anal cancer. Ann Oncol 26(S4):iv38
153.
154.
Bass EM et al (1997) Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 40(4):440–442 PubMed
155.
Millan M et al (2010) Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units. Colorectal Dis 12(7):e88–e92 PubMed
156.
Person B et al (2012) The impact of preoperative stoma site marking on the incidence of complications, quality of life, and patient’s independence. Dis Colon Rectum 55(7):783–787 PubMed
157.
Pan YB et al (2018) Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review. Acta Oncol 57(11):1427–1437 PubMed
158.
159.
160.
161.
Institute of Medicine Committee on Psychosocial Services to Cancer Patients/Families in a Community, S (2008) The national academies collection: reports funded by national institutes of health, in cancer care for the whole patient: meeting psychosocial health needs, N.E. Adler and A.E.K. Page. National Academies Press (US), National Academy of Sciences, Washington (DC)
162.
Kusch M et al (2014) Integrated psychooncology: implementation of psychooncological health care at the Center for Integrated Oncology Cologne—Bonn. Dtsch Med Wochenschr 139(46):2357–2360 PubMed
163.
Mortensen GL, Lundby L (2015) Patients use normalisation techniques to cope with the quality-of-life effects of anal cancer. Dan Med J 62(3):A5020 PubMed
164.
Sodergren SC et al (2015) Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Support Care Cancer 23(12):3613–3623 PubMed
165.
Chakrabarti S et al (2019) Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. J Gastrointest Oncol 10(2):171–178 PubMedPubMedCentral
166.
Jelinek SK et al (2015) Anal superficially invasive squamous cell carcinoma (SISCCA) treatments and outcomes. Sex Health 12(1):82
167.
Greenall MJ et al (1985) Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. Am J Surg 149(1):95–101 PubMed
168.
Kuss O, Blettner M, Borgermann J (2016) Propensity score: an alternative method of analyzing treatment effects. Dtsch Arztebl Int 113(35–36):597–603 PubMedPubMedCentral
169.
Hatfield P, Cooper R, Sebag-Montefiore D (2008) Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys 70(2):419–424 PubMed
170.
Coccaro EF et al (2015) Morphometric analysis of amygdla and hippocampus shape in impulsively aggressive and healthy control subjects. J Psychiatr Res 69(9034):80–86 PubMedPubMedCentral
171.
Northover J et al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 102(7):1123–1128 PubMedPubMedCentral
172.
Buckstein M et al (2018) A population-based cohort analysis of chemoradiation versus radiation alone for definitive treatment of stage I anal cancer in older patients. Dis Colon Rectum 61(7):787–794 PubMedPubMedCentral
173.
174.
Zilli T et al (2012) Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? Radiother Oncol 102(1):62–67 PubMed
175.
Flam M et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14(9):2527–2539 PubMed
176.
177.
Ajani JA et al (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299(16):1914–1921 PubMed
178.
Gunderson LL et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30(35):4344–4351 PubMedPubMedCentral
179.
180.
Matzinger O et al (2009) Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 45(16):2782–2791 PubMed
181.
Goodman KA et al (2017) Capecitabine with Mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 98(5):1087–1095 PubMed
182.
Jones CM et al (2018) Toxicity, tolerability, and compliance of concurrent capecitabine or 5‑Fluorouracil in radical management of anal cancer with single-dose Mitomycin‑C and intensity modulated radiation therapy: evaluation of a national cohort. Int J Radiat Oncol Biol Phys 101(5):1202–1211 PubMed
183.
Meulendijks D et al (2014) Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 111(9):1726–1733 PubMedPubMedCentral
184.
Peixoto RD et al (2016) A comparison between 5‑fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. J Gastrointest Oncol 7(4):665–672 PubMedPubMedCentral
185.
White EC et al (2015) Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin‑C. Radiother Oncol 117(2):240–245 PubMed
186.
Yeung R et al (2014) One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity. Curr Oncol 21(3):e449–56 PubMedPubMedCentral
187.
Peiffert D et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30(16):1941–1948 PubMed
188.
Prasad RN, Elson J, Kharofa J (2018) The effect of dose escalation for large squamous cell carcinomas of the anal canal. Clin Transl Oncol 20(10):1314–1320 PubMed
189.
Rattan R et al (2016) Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. Ann Transl Med 4(4):70–27004217 PubMedPubMedCentral
190.
Bryant AK et al (2018) Intensity modulated radiation therapy versus conventional radiation for anal cancer in the veterans affairs system. Int J Radiat Oncol Biol Phys 102(1):109–115 PubMed
191.
Elson JK, Kachnic LA, Kharofa JR (2018) Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study. Cancer 124(22):4383–4392 PubMed
192.
Pollom EL et al (2017) The impact of intensity modulated radiation therapy on hospitalization outcomes in the SEER-medicare population with anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 98(1):177–185 PubMedPubMedCentral
193.
Chuong MD et al (2013) Intensity-modulated radiation therapy vs. 3D Conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res 6(2):39–45 PubMedPubMedCentral
194.
Koerber SA et al (2014) Efficacy and toxicity of chemoradiation in patients with anal cancer—a retrospective analysis. Radiat Oncol 9:113 PubMedPubMedCentral
195.
Koerber SA et al (2019) Chemoradiation in female patients with anal cancer: patient-reported outcome of acute and chronic side effects. Tumori 105(2):174–180 PubMed
196.
Spencer CR et al (2014) Outcomes after IMRT compared to 3DCRT for squamous cell carcinoma of the anus. Int J Radiat Oncol 90(1):S400–S401
197.
Weber HE et al (2015) Volumetric intensity-modulated arc therapy vs. 3‑dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival. Strahlenther Onkol 191(11):827–834 PubMed
198.
Yeung R et al (2015) Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. Radiat Oncol 10:92 PubMedPubMedCentral
199.
Konski A et al (2008) Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 72(1):114–118 PubMedPubMedCentral
200.
Geltzeiler CB et al (2014) Chemoradiotherapy with a radiation boost for anal cancer decreases the risk for salvage abdominoperineal resection: analysis from the national cancer data base. Ann Surg Oncol 21(11):3616–3620 PubMed
201.
Budde CN et al (2014) Boost radiation treatment for anal cancer decreases the risk for lifetime colostomy: analysis from the national cancer data base (NCDB). Ann Surg Oncol 1:S76
202.
Franco P et al (2018) Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study. Radiat Oncol 13(1):172 PubMedPubMedCentral
203.
Althaqfi S et al (2015) 631 Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period. Eur J Cancer 51:S126
204.
Hannoun-Levi JM et al (2011) High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys 80(3):712–720 PubMed
205.
Oehler-Janne C et al (2007) Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 6(3):218–226 PubMed
206.
Arcelli A et al (2019) Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: a mono-institutional retrospective analysis. J Contemp Brachytherapy 11(1):21–27 PubMedPubMedCentral
207.
Moureau-Zabotto L et al (2013) Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys 85(3):e135–e142 PubMed
208.
Kouloulias V et al (2005) Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 28(1):91–99 PubMed
209.
Ott OJ et al (2019) Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol 195(7):607–614 PubMed
210.
Bruggmoser G et al (2012) Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol 188(Suppl 2):198–211 PubMed
211.
Chapet O et al (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63(5):1316–1324 PubMed
212.
Scricciolo M et al (2015) Optimum time to assess complete response following radiochemotherapy in anal canal cancer patients. Radiother Oncol 1:S658
213.
Lee GC et al (2019) Waiting 〉3 months between radiation and salvage APR is associated with positive margins in patients with anal cancer treated with concurrent chemoradiation. Dis Colon Rectum 62(6):e286
214.
Houard C et al (2017) Role of (18)F-FDG PET/CT in posttreatment evaluation of anal carcinoma. J Nucl Med 58(9):1414–1420 PubMed
215.
Teagle AR et al (2016) Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer. Nucl Med Commun 37(10):1038–1045 PubMed
216.
Kochhar R et al (2017) The assessment of local response using magnetic resonance imaging at 3‑ and 6‑month post chemoradiotherapy in patients with anal cancer. Eur Radiol 27(2):607–617 PubMed
217.
218.
Abunassar M et al (2015) Review of anal cancer patients at the Ottawa hospital. Eur J Surg Oncol 41(5):653–658 PubMed
219.
Ferenschild FT et al (2005) Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg 29(11):1452–1457 PubMed
220.
Mullen JT et al (2007) Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 14(2):478–483 PubMed
221.
Papaconstantinou HT et al (2006) Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Dis 8(2):124–129 PubMed
222.
Roohipour R et al (2008) Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 51(2):147–153 PubMed
223.
Stewart D et al (2007) Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg 11(12):1744–1751 PubMed
224.
Ko G et al (2019) A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. Colorectal Dis 21(6):632–650 PubMed
225.
Fraunholz I et al (2010) Concurrent chemoradiotherapy with 5‑fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys 76(5):1425–1432 PubMed
226.
Nyitray AG et al (2018) A phase II clinical study to assess the feasibility of self and partner anal examinations to detect anal canal abnormalities including anal cancer. Sex Transm Infect 94(2):124–130 PubMed
227.
Duimering A et al (2019) Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma. Radiother Oncol 136:21–28 PubMed
228.
Jones MP et al (2019) FDG-PET parameters predict for recurrence in anal cancer—results from a prospective, multicentre clinical trial. Radiat Oncol 14(1):140 PubMedPubMedCentral
229.
Lampejo T et al (2010) Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 103(12):1858–1869 PubMedPubMedCentral
230.
Gilbert DC et al (2019) Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. Br J Cancer 120(2):256–268 PubMed
231.
Faivre C et al (1999) 5‑fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 86(10):861–865 PubMed
232.
Portelance L et al (2014) A multidisciplinary approach to the management of patients diagnosed with stage IV anal canal cancer: a multi-institutional retrospective study. Oncology. Conference: 96th Annual Meeting of the American Radium Society, ARS, 2014. 28(1S)..
233.
Sclafani F et al (2017) Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients. Oncologist 22(4):402–408 PubMedPubMedCentral
234.
Tanum G (1993) Treatment of relapsing anal carcinoma. Acta Oncol 32(1):33–35 PubMed
235.
Wilking N et al (1985) Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 15(3):300–302 PubMed
236.
Kim R et al (2014) Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology 87(2):125–132 PubMed
237.
Hong DS et al (2018) Evaluation of prexasertib, a checkpoint Kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma. Clin Cancer Res 24(14):3263–3272 PubMedPubMedCentral
238.
Morris VK et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446–453 PubMedPubMedCentral
239.
Ott PA et al (2017) Safety and antitumor activity of the anti-PD‑1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 28(5):1036–1041 PubMedPubMedCentral
240.
Kim DW et al (2017) EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience. Oncology 92(4):190–196 PubMed
241.
Rogers JE et al (2016) Epidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs 27(8):804–808 PubMed
242.
Kim S et al (2018) Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 19(8):1094–1106 PubMed
243.
Eng C et al (2014) The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 5(22):11133–11142 PubMedPubMedCentral
244.
Mondaca S et al (2019) FOLFCIS treatment and genomic correlates of response in advanced anal squamous cell cancer. Clin Colorectal Cancer 18(1):e39–e52 PubMed
245.
Abdelazim YA et al (2019) Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review. Cancer 125(12):2115–2122 PubMed
246.
Repka MC et al (2017) Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting. Cancer Med 6(11):2497–2506 PubMedPubMedCentral
247.
Wang Y et al (2019) Definitive pelvic radiotherapy and survival of patients with newly diagnosed metastatic anal cancer. J Natl Compr Canc Netw 17(1):29–37 PubMed
248.
Evesque L et al (2017) Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience. Dis Colon Rectum 60(8):785–791 PubMed
249.
Omichi K et al (2017) Long term outcome after resection of liver metastases from squamous cell carcinoma. Eur J Surg Oncol 43(11):2129–2134 PubMed
250.
251.
Radbruch L, Payne S, European Association for Palliative Care (EAPC) (2009) White Paper on standards and norms for hospice andpalliative care in Europe: part 1. Eur J Palliat Care 16(6):278–289
252.
Alt-Epping B, Nauck F, Schneider N (2012) Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten. Hausarzt 11:43–46
253.
254.
Adler K et al (2017) Integration of palliative care into intensive care : systematic review. Anaesthesist 66(9):660–666 PubMed
255.
Dalgaard KM et al (2014) Early integration of palliative care in hospitals: a systematic review on methods, barriers, and outcome. Palliat Support Care 12(6):495–513 PubMed
256.
Davis MP et al (2015) A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med 4(3):99–121 PubMed
257.
Gaertner J et al (2017) Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. BMJ 357:j2925 PubMed
258.
Hui D et al (2015) Integration of oncology and palliative care: a systematic review. Oncologist 20(1):77–83 PubMed
259.
Hui D et al (2016) Referral criteria for outpatient palliative cancer care: a systematic review. Oncologist 21(7):895–901 PubMedPubMedCentral
260.
Tassinari D et al (2016) Early palliative care in advanced oncologic and non-oncologic chronic diseases: a systematic review of literature. Rev Recent Clin Trials 11(1):63–71 PubMed
261.
Ferrell BR et al (2017) Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(1):96–112 PubMed
262.
263.
Mittal R et al (2010) Transanal excision of anorectal lesions—a single centre experience. Trop Gastroenterol 31(1):65–68 PubMed
264.
Schlag P (1989) How does quality of life modify indications for palliative surgical measures? Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir 1989:129–135
265.
Cramp F, Byron-Daniel J (2012) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11:CD6145 PubMed
266.
Streckmann F et al (2014) Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44(9):1289–1304 PubMed
267.
Metadaten
Titel
S3-Leitlinie Analkarzinom
Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen
verfasst von
Prof. Dr. med. Felix Aigner, MBA
PD Dr. med. Robert Siegel
Dr. med. Ricardo N. Werner
PD Dr. med. Stefan Esser
Prof. Dr. med. Mark Oette
PD Dr. med. Gerhard Weyandt
Prof. Dr. med. Volker Kahlke
Dr. med. Adal Saeed
Prof. Dr. med. Matthias Turina
Dr. med. Franz A. Mosthaf
Prof. Dr. med. Stefan Dresel
PD Dr. med. Steffen Simon
Prof. Dr. med. Gerald Niedobitek
Dr. med. Stephan Koswig
Prof. Dr. Volker Budach
Dr. med. Jan Schmielau
Prof. Dr. med. Hans-Rudolf Raab
Dipl. med. Gerhard Faber
Dr. rer. medic. Bianca Senf
Prof. Dr. med. Claus Rödel
Prof. Dr. med. E. Fokas
Dr. med. Rolf Mahlberg
Dr. med. Maria Steingräber
Prof. Dr. med. Johannes Weßling
Prof. Dr. med. Ulrike Wieland
Prof. Dr. med. Alois Fürst
Dr. med. Petra Lugger
Prof. Dr. med. Franz‑Josef Prott
Dr. med. Irmgard Kronberger
Dr. med. Stephan Baumeler
Dr. Christine Maurus
Erich Grohmann
Matthew Gaskins, MPH
Gabriela L. Avila Valle, M.Sc.
Martin Dittmann
Deutsche Gesellschaft für Koloproktologie
Deutsche AIDS Gesellschaft
Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten
Deutsche Dermatologische Gesellschaft
Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie – AG Coloproktologie
Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie – AG „Funktionalität in der kolorektalen Chirurgie“
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
Deutsche Gesellschaft für Nuklearmedizin
Deutsche Gesellschaft für Palliativmedizin
Deutsche Gesellschaft für Pathologie
Deutsche Krebsgesellschaft – AG Onkologische Pathologie
Deutsche Gesellschaft für Radioonkologie
Deutsche Gesellschaft für Rehabilitationswissenschaften
Deutsche Krebsgesellschaft – Assoziation Chirurgische Onkologie
Deutsche Krebsgesellschaft – AG Onkologische Rehabilitation und Sozialmedizin
Deutsche Krebsgesellschaft – AG Psychoonkologie
Deutsche Krebsgesellschaft – AG Radiologische Onkologie
Deutsche Krebsgesellschaft – AG Supportive Maßnahmen in der Onkologie
Deutsche Röntgengesellschaft
Gesellschaft für Virologie
Paul-Ehrlich-Gesellschaft für Chemotherapie
Berufsverband der Coloproktologen Deutschlands
Berufsverband der Deutschen Strahlentherapeuten
Österreichische Arbeitsgemeinschaft für Coloproktologie
Schweizerische Arbeitsgemeinschaft für Koloproktologie
Deutsche ILCO
Publikationsdatum
14.06.2021
Verlag
Springer Medizin
Erschienen in
coloproctology / Ausgabe 3/2021
Print ISSN: 0174-2442
Elektronische ISSN: 1615-6730
DOI
https://doi.org/10.1007/s00053-021-00530-8

Weitere Artikel der Ausgabe 3/2021

coloproctology 3/2021 Zur Ausgabe

Mitteilungen der CACP

Standardisierung der präoperativen Ausbreitungsdiagnostik beim Rektumkarzinom mittels MRT

Stoma- und Wundmanagement

Digitalisierungsvorschub für spezialisierte Pflege?

Journal Club

Versorgung des kolorektalen Karzinoms in England

Editorial

Leitlinien sind eine wertvolle Orientierung in der Patientenbehandlung

Mitteilungen des BCD und der DGK

Mitteilungen des BCD und der DGK

CME

Update: Vorsorge, Diagnostik und Therapie des Rektumkarzinoms

Passend zum Thema

ANZEIGE

Kennen Sie den Stellenwert der Pneumokokken-Serotypen 22F & 33F?

Pneumokokken-Erkrankungen stellen ein ernstes Risiko für Säuglinge und Kleinkinder dar. Was die Pneumokokken-Serotypen 22F und 33F damit zu tun haben erfahren Sie hier.
ANZEIGE

15 Jahre HPV-Impfung: Wo stehen wir?

HPV-Impfstoffe sind mittlerweile seit mehr als 15 Jahren in Deutschland verfügbar. Mehr zur Entwicklung der HPV-Impfung und der aktuellen Situation.
ANZEIGE

Impfungen – vom Säugling bis zum Senior

Als eines der global führenden Gesundheitsunternehmen besitzt MSD mehr als 100 Jahre Erfahrung in der Entwicklung von Impfstoffen. Hier finden Sie Informationen zu einigen der von der STIKO empfohlenen Immunisierungen, z.B. der MMRV- und der HPV-Impfung sowie der Pneumokokken-Impfung für Senioren.

Bildnachweise